Nasal cavity soft mist administration device

Abstract

The utility model discloses a nasal cavity soft mist administration device, which relates to the technical field of administration devices and comprises an administration main body and a mist spray adapter, the spray adapter is connected with the end part of the dosing main body; a concave part is arranged on the administration main body, and divides an inner cavity of the administration main body into a first accommodating cavity and a second accommodating cavity which are communicated with each other; a micro-pore chip is loaded on the spray adapter, and the micro-pore chip is arranged right opposite to the end part of the drug administration main body. The nasal cavity soft fog administration device provided by the utility model is portable to use, and can efficiently and quickly atomize a single-dose sterile solution or suspension which does not contain preservatives into soft fog which moves slowly, and atomized liquid drops are small in particle size and uniform in distribution.

Description

TECHNICAL FIELD

[0001] The utility model relates to a dosing device technical field, especially a nasal cavity soft mist dosing device. BACKGROUND

[0002] The human intranasal drug delivery area can be roughly divided into five parts, which are area one olfactory region, area two middle turbinate, area three inferior turbinate, area four nasopharynx and area five nasal vestibule. For many years, due to the influence of local drug delivery mechanism and the particle size and speed of the drug sprayed by the nasal drug delivery device, the action area of the nasal spray mainly concentrates in the nasal vestibule, and the treatment field of the nasal spray mainly concentrates in the field of rhinitis and allergy, and the drugs are mainly antihistamine drugs and hormone drugs. With the deepening of the research on intranasal drug delivery area, the drug can enter the central nervous system through the nasal-brain drug delivery pathway, and the treatment field of the nasal spray is expected to expand to the central nervous system, such as headache (including migraine), epilepsy, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, motion sickness, cerebrovascular disease (including stroke and cerebral infarction, etc.), traumatic brain injury, spinal cord injury, anxiety, depression, insomnia, drowsiness, neuroinfection and neuroimmunity (including meningitis, AIDS, cerebral malaria and multiple sclerosis, etc.), neurodevelopmental disorders, schizophrenia, brainstem glioma, opioid addiction, dry eye syndrome and attention deficit hyperactivity disorder (ADHD) and other diseases.

[0003] The key technical difficulty of the drug entering the central nervous system through the nasal-brain drug delivery pathway is that the drug needs to be atomized into soft mist with a certain particle size range in the nasal cavity. The liquid droplet particle size distribution range of the spray device of the various nasal sprays on the market is relatively wide after atomization, most of the liquid droplet particle size is greater than 50 μm, and the drug spraying speed is fast, which leads to a large amount of drug liquid droplets deposited in the nasal vestibule area during drug delivery, and the coverage of the remaining functional areas is very low, which greatly affects the bioavailability of the drug, and seriously affects the efficacy of the nasal spray.

[0004] In addition, most of the various nasal sprays on the market are multi-dose systems, and a bacteriostatic agent needs to be added to the drug to ensure the sterility during the use of the drug, and the irritability of the bacteriostatic agent limits the use of the nasal spray in sensitive patients, elderly patients and infant patients. Therefore, single-dose sterile nasal sprays without preservatives have significant compliance advantages and broad market prospects.

[0005] Therefore, a nasal cavity soft mist drug delivery device is developed, which can atomize the drug into soft mist with small particle size (5-500 μm), uniform distribution and slow movement, so that the nasal cavity drug delivery area is expanded from the vestibule of the nasal cavity to the olfactory area, middle turbinate, inferior turbinate and nasopharynx area, the bioavailability of various nasal spray drugs is significantly improved, and the indications of nasal cavity drug delivery are expanded to diseases such as headache (including migraine), epilepsy, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, motion sickness, cerebrovascular disease (including stroke and cerebral infarction), traumatic brain injury, spinal cord injury, anxiety, depression, insomnia, drowsiness, neurological infection and neuroimmunity (including meningitis, AIDS, cerebral malaria and multiple sclerosis), neurological developmental disorder, schizophrenia, brain stem cell tumor, opiate addiction, dry eye syndrome and attention deficit hyperactivity disorder (ADHD). In addition, single-dose nasal spray without preservatives can ensure the compliance and portability of sensitive patients, elderly patients and infant patients. Content of the utility model

[0006] In order to solve the above technical problems, the utility model provides a kind of nasal cavity soft mist drug delivery device, can be atomized into soft mist with uniform particle size, slow diffusion for single-dose sterile solution or suspension without preservative, so that the nasal cavity drug delivery area is expanded from the vestibule of the nasal cavity to the olfactory area, middle turbinate, inferior turbinate and nasopharynx area, the bioavailability of nasal spray drug is significantly improved, and the indications of nasal cavity drug delivery are expanded to diseases such as headache (including migraine), epilepsy, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, motion sickness, cerebrovascular disease (including stroke and cerebral infarction), traumatic brain injury, spinal cord injury, anxiety, depression, insomnia, drowsiness, neurological infection and neuroimmunity (including meningitis, AIDS, cerebral malaria and multiple sclerosis), neurological developmental disorder, schizophrenia, brain stem cell tumor, opiate addiction, dry eye syndrome and attention deficit hyperactivity disorder (ADHD).

[0007] In order to realize the purpose of the utility model, the technical scheme adopted by the utility model is as follows:

[0008] A kind of nasal cavity soft mist drug delivery device, including drug delivery main body and spray adapter;Spray adapter is connected with the end of drug delivery main body;Drug delivery main body is equipped with recess, and recess divides the internal cavity of drug delivery main body into the first accommodating cavity and the second accommodating cavity communicated;Spray adapter is loaded with microporous chip, and microporous chip is directly opposite to the end position of drug delivery main body.

[0009] Based on the above technical scheme, further, it also includes the connecting piece for connecting spray adapter and drug delivery main body, and the connecting piece is provided with external thread structure, and the internal thread structure in spray adapter, and the connecting piece and spray adapter are connected by thread.

[0010] Based on the above technical scheme, further, the spray adapter is further provided with a guide part, the connecting piece is provided with a through hole, the guide part is arranged in the through hole, and one end of the guide part is a pointed structure, and the pointed structure is provided with a liquid outlet hole.

[0011] Based on the above technical scheme, further, the through hole inner wall is provided with a first limiting part and a second limiting part, and a first groove structure is arranged between the first limiting part and the second limiting part.

[0012] Based on the above technical scheme, further, the second limiting part one side wall and the connecting piece inner wall are provided with an inclined angle.

[0013] Based on the above technical scheme, further, the first convex part is matched with the first groove.

[0014] Based on the above technical scheme, further, the second convex part is arranged on the outer surface of the drug administration body, a second groove is arranged on the connecting piece, and one end of the second convex part is extended and limited into the second groove.

[0015] Based on the above technical scheme, further, the drug administration body is provided with an external thread structure, and the drug administration body is threadedly connected with the spray adapter.

[0016] Based on the above technical scheme, further, the lower end of the drug administration body is provided with a label part, and an information label is attached to the label part.

[0017] Based on the above technical scheme, further, a plurality of spray holes are arranged on the micropore chip, the diameter of the spray hole ranges from 1 μm to 100 μm, the drug can be atomized into soft mist with a particle size of 5-500 μm, and preferably 20-150 μm.

[0018] Based on the above technical scheme, further, the drug administration body is a structure containing a drug produced by blow molding and sealing, and the drug in the drug administration body is a single-dose sterile solution or suspension without preservatives.

[0019] Compared with the prior art, the beneficial effects of the utility model are as follows:

[0020] The utility model provides a nasal cavity soft mist dosing device, uses portable, can be single dose sterile solution or suspension liquid that does not contain antiseptic high efficiency, fast atomization is slow moving soft mist, the liquid drop particle size after atomization is smaller and is evenly distributed (5-500um), can more diffusion and deposit in all intranasal area, has improved patient's total coverage and unit area coverage of each intranasal area significantly, thereby greatly improve the bioavailability of medicine. Secondly, compared with most multi-dose nasal spray on the market, the delivery advantage is remarkable, provides an effective solution for sensitive patients, elderly patients and infant patients and other patients. BRIEF DESCRIPTION OF DRAWINGS

[0021] Figure 1 It is the front view of the nasal cavity soft mist dosing device of the utility model,

[0022] Figure 2 It is Figure 1 The side view of the nasal cavity soft mist dosing device of the utility model,

[0023] Figure 3 It is Figure 2 The partial structure schematic view of the nasal cavity soft mist dosing device of the utility model,

[0024] Figure 4 It is the structure schematic view of the multiple dosing devices of the utility model,

[0025] Figure 5 It is the front view of the dosing device of the utility model without setting connecting piece,

[0026] Figure 6 It is the side view of the dosing device of the utility model without setting connecting piece,

[0027] Figure 7 It is the structure schematic view of the multiple dosing devices of the utility model without setting connecting piece,

[0028] Reference Signs: 1. dosing main body, 2. spray adapter, 3. microporous chip, 4. connecting piece, 5. label part, 6. guide part, 7. first limit part, 8. second limit part, 9. first recess, 10. first convex part, 11. second convex part, 12. second recess, 13. tip structure, 14. first containing cavity, 15. second containing cavity, 16. end cover, 17. recess. DETAILED DESCRIPTION

[0029] In order to make the purpose and technical scheme of the utility model more clear, the technical scheme of the utility model will be described clearly and completely in combination with examples.

[0030] Example 1

[0031] As Figures 1-7As shown, a nasal cavity soft mist administration device comprises an administration main body 1 and a spray adapter 2; the spray adapter 2 is connected with the end of the administration main body 1; the administration main body 1 is provided with a recess 17, which divides the internal cavity of the administration main body 1 into a first containing cavity 14 and a second containing cavity 15 in communication; the spray adapter 2 is loaded with a microporous chip 3, which is directly opposite the end position of the administration main body 1. One embodiment is as shown in Figure 1 The spray adapter 2 is connected with the end of the administration main body 1 through a connecting piece 4; another embodiment is as shown in Figure 5 The spray adapter 2 is directly connected with the end of the administration main body 1 through a threaded structure.

[0032] Specifically, the microporous chip 3 is provided with a plurality of spray holes, the diameter of the spray holes ranges from 1 μm to 100 μm, and further preferably from 1 μm to 10 μm. It needs to be explained that the microporous chip 3 refers to a structure in which a specified size of spray hole is opened on a chip material such as silicon-based, carbon-based, copper, stainless steel, etc., and by setting different sizes of the hole diameter of the spray hole, the liquid medicine in the internal cavity can be sprayed out to form a soft mist phenomenon, which is a conventional phenomenon in the art. The connecting piece 4 is provided with an external thread structure, the inside of the spray adapter 2 is an internal thread structure, and the connecting piece 4 and the spray adapter 2 are threadedly connected. The spray adapter 2 is also provided with a guide portion 6, the connecting piece 4 is provided with a through hole, the guide portion 6 is arranged in the through hole, and one end of the guide portion 6 is a pointed structure 13, the pointed structure 13 is provided with a liquid outlet hole, and the pointed structure 13 is provided to facilitate the communication between the spray adapter 2 and the administration main body 1. In use, the pointed structure 13 is inserted into the end of the administration main body 1, the structure is inclined to insert the top of the spray adapter 2 into the nasal cavity, the medicine in the administration main body 1 flows into the first containing cavity 14, and then enters the spray adapter 2 through the liquid outlet hole of the pointed structure 13. By extruding the second containing cavity 15, a pressure is formed, and the solution entering the spray adapter 2 is sprayed out through the spray holes on the microporous chip 3 under the action of the pressure. The inner wall of the through hole is provided with a first limiting portion 7 and a second limiting portion 8, and a first groove 9 structure is arranged between the first limiting portion 7 and the second limiting portion 8. The side wall of the second limiting portion 8 and the inner wall of the connecting piece 4 are provided with an inclination angle, and the inclination structure is arranged to facilitate the installation of the end of the administration main body 1 and the connecting piece 4, and to avoid unnecessary damage to the end of the administration main body 1 and the connecting piece 4 due to excessive friction. The end of the administration main body 1 is provided with a first protrusion 10, and the first protrusion 10 cooperates with the first groove 9. The lower end of the administration main body 1 is provided with a labeling portion 5, and an information label is attached to the labeling portion 5. The outer surface of the administration main body 1 is provided with a second protrusion 11, a second groove 12 is opened on the connecting piece 4, and one end of the second protrusion 11 extends and limits into the second groove 12.

[0033] The size and material of the administration body 1 can be adjusted according to actual needs. For example, the material of the administration body 1 can be selected from polyethylene, LDPE, LLDPE, HDPE, polypropylene, etc. The liquid medicine in the administration body 1 is a single-dose sterile solution or suspension without preservatives. The bottle type, size and internal volume of the LDPE bottle can be adjusted to meet the dosage requirements of different medicines.

[0034] The administration principle of the device is as follows: before use, the end cap 16 at the upper end of the administration body 1 is unscrewed, and the spray adapter 2 is directly screwed with the end of the administration body 1. It should be noted that whether it is a soft material or a hard material, the spray adapter 2 can be screwed with the end of the administration body 1, or the spray adapter 2 is connected with the end of the administration body 1 through the bayonet structure of the connecting piece 4. When the connecting piece 4 is used, the connecting piece 4 is installed on the upper end of the administration body 1, the first limiting part 7, the second limiting part 8 and the first groove 9 of the connecting piece 4 are engaged with the first protruding part 10 of the administration body 1, and the second groove 12 of the connecting piece 4 is engaged with the second protruding part 11 of the administration body 1. The spray adapter 2 is inserted into the passage of the connecting piece 4, and the spray adapter 2 pierces the top of the administration body 1 through the pointed structure 13 and is inserted into the administration body 1. Specifically, during use, the administration body 1 is inverted or placed horizontally, so that the medicine in the second containing cavity 15 of the administration body 1 enters the first containing cavity 14, and the upper end of the spray adapter 2 is inserted into the nasal cavity. Head up, tilt the administration device, so that the medicine is concentrated in the first containing cavity 14 of the administration body, manually squeeze the second containing cavity 15 of the administration body 1, the medicine enters the spray adapter 2 through the aperture on the pointed structure 13 of the spray adapter 2, the medicine is atomized to produce soft mist through the micro-porous chip 3, and the medicine enters the nasal cavity to realize administration. It should be noted that the pressure of manual extrusion is greater than 80Kpa, which has been verified to be sufficient to realize the ejection of medicine through the spray hole and the generation of mist or soft mist phenomenon. Further, the meaning of soft mist in this embodiment is that the mist droplet size is small, the spray speed is slow, and the single spray lasts for a long time. The output mist is called "soft mist". In the extrusion process of the device, the soft mist is generated by the collision of the aperture size of the spray hole and the structure of the spray adapter 2, and the target particle size of the output soft mist is 5-500μm, and the best range is 20-150μm.

[0035] Example 2

[0036] Based on the structure of the nasal soft mist administration device described in Example 1, the distribution of the medicine in the nasal cavity after the administration of the administration device and the commercially available nasal spray device is compared as follows:

[0037] A certain amount of calcein powder was dissolved in 1 mol / L sodium hydroxide solution and mixed with 25% glycerol solution to prepare a fluorescent indicator solution with a certain viscosity, which was filled into the nasal soft mist administration device and the commercially available nasal spray device, respectively, and sprayed on the silica gel nasal model. An ultraviolet lamp was used as the ultraviolet light source, and the fluorescent images of different groups were collected in a dark room by a digital camera. The pictures were analyzed by software to calculate the coverage rate of each region, so as to compare the intranasal distribution of different devices. The results are shown in Table 1.

[0038] Table 1

[0039]

[0040] From the imaging comparison results of the silica gel nasal model, compared with the commercially available nasal spray device, the nasal soft mist administration device disclosed in the present application not only has a much higher coverage rate in the nasal vestibule, but also has a significant advantage in total coverage rate and coverage rate in other regions (except the nasopharynx region), which indicates that the nasal soft mist administration device can greatly improve the bioavailability of each nasal spray.

[0041] For example, the particle size distribution of the mist droplets after atomization of the device and the existing commercially available device is compared, as follows:

[0042] 1. Prepare the sumatriptan nasal spray liquid as shown in Table 2, and fill it into the LDPE small bottle produced by blow molding, which is the main body for administration. Connect the nasal spray adapter with the LDPE small bottle as sample 1. Fill the sumatriptan nasal spray liquid into the commercially available nasal spray device as sample 2. Measure the particle size distribution of the mist droplets of the two samples by the new Partech laser particle size tester, and compare the results as shown in Table 3.

[0043] Table 2 Sumatriptan nasal spray liquid

[0044]

[0045] Table 3

[0046]

[0047] According to the results in Table 2 and Table 3, compared with the atomization effect of the commercially available nasal spray device under the same conditions, the D10-D90 data show that the D90 of the nasal soft mist administration device is 24.67 μm, and the D50 is 16.05 μm, while the D90 of the commercially available device is 78.02 μm, and the D50 is 35.84 μm. The particle size distribution range of the mist droplets atomized by the nasal soft mist administration device is relatively narrow, and the uniformity has a significant advantage. Moreover, the particle size range of the mist droplets sprayed by the device meets the set range.

[0048] In yet another embodiment, the nasal soft mist drug delivery device is compared with a commercially available nasal inhalation device in terms of the droplet size distribution of the azelastine hydrochloride and fluticasone propionate medicament, as follows: An azelastine hydrochloride and fluticasone propionate nasal spray is prepared, as shown in Table 4, and filled into a small bottle of LDPE or the like material for the nasal soft mist drug delivery device, and a nasal spray adapter is connected to the small bottle of LDPE or the like material, as sample 3. An azelastine hydrochloride and fluticasone propionate nasal spray is filled into a commercially available nasal spray device, as sample 4. The droplet size distribution of the two samples is determined by a new Malvern laser particle size tester, and compared, and the results are shown in Table 5.

[0049] Table 4 Azelastine hydrochloride nasal spray liquid

[0050]

[0051] Table 5

[0052]

[0053] According to the results in Tables 4 and 5, compared with the atomization effect of the spray device of the commercially available nasal spray under the same conditions, the D10-D90 data show that the D90 of the nasal soft mist drug delivery device is 26.06 μm, and the D50 is 16.04 μm, while the D90 of the commercially available device is 77.95 μm, and the D50 is 36.07 μm. The droplet size distribution of the nasal soft mist drug delivery device is narrow and uniform, and has a significant advantage. Moreover, the droplet size range sprayed by the device meets the set range.

[0054] In other embodiments, the nasal soft mist drug delivery device is compared with a commercially available device in terms of the droplet size distribution of the budesonide medicament, as follows: A budesonide nasal spray is prepared, as shown in Table 6, and filled into a small bottle of LDPE or the like material for the nasal soft mist drug delivery device, and a nasal spray adapter is connected to the small bottle of LDPE or the like material, as sample 5. A budesonide nasal spray is filled into a commercially available nasal spray device, as sample 6. The droplet size distribution of the two samples is determined by a new Malvern laser particle size tester, and compared, and the results are shown in Table 7.

[0055] Table 6 Budesonide nasal spray liquid

[0056]

[0057] Table 7

[0058]

[0059] According to the results of the above Tables 6 and 7, compared with the atomization effect of the spray device of the commercially available nasal spray under the same conditions, in combination with the D10-D90 data, for example, the D90 of the nasal cavity soft mist drug delivery device is 27.00 pm, the D50 is 16.88 pm, while the D90 of the commercially available device is 76.89 pm, and the D50 is 36.06 pm. The nasal cavity soft mist drug delivery device in the present scheme has a narrow and uniform droplet size distribution. And the droplet size range sprayed by the device meets the set range.

[0060] In other embodiments, the droplet size distribution of fluticasone propionate sprayed by the nasal cavity soft mist drug delivery device and the commercially available device is compared. The specific analysis is as follows: fluticasone propionate nasal spray is prepared, as shown in Table 8, and is filled into a small bottle made of LDPE and other materials of the nasal cavity soft mist drug delivery device, and the nasal spray adapter is connected to the small bottle made of LDPE and other materials, as sample 7. Fluticasone propionate nasal spray is filled into a commercially available nasal spray device, as sample 8. The droplet size distribution of the two samples is determined by a new Patek laser particle size tester and compared. The results are shown in Table 9.

[0061] Table 8 Fluticasone propionate nasal spray

[0062]

[0063] Table 9

[0064]

[0065] According to the results of the above Tables 8 and 9, compared with the atomization effect of the spray device of the commercially available nasal spray under the same conditions, in combination with the D10-D90 data, for example, the D90 of the nasal cavity soft mist drug delivery device is 24.67 pm, the D50 is 16.05 pm, while the D90 of the commercially available device is 80.14 pm, and the D50 is 37.21 pm. The nasal cavity soft mist drug delivery device in the present scheme has a narrow and uniform droplet size distribution. And the droplet size range sprayed by the device meets the set range.

[0066] In other embodiments, the droplet size distribution of granisetron hydrochloride sprayed by the nasal cavity soft mist drug delivery device and the commercially available device is compared. The specific analysis is as follows: granisetron hydrochloride nasal spray is prepared, as shown in Table 10, and is filled into a small bottle made of LDPE and other materials of the nasal cavity soft mist drug delivery device, and the nasal spray adapter is connected to the small bottle made of LDPE and other materials, as sample 9. Granisetron hydrochloride nasal spray is filled into a commercially available nasal spray device, as sample 10. The droplet size distribution of the two samples is determined by a new Patek laser particle size tester and compared. The results are shown in Table 11.

[0067] Table 10 Granisetron hydrochloride nasal spray

[0068]

[0069] Table 11

[0070]

[0071] According to the results of the above table 10 and table 11, compared with the spray droplets generated by the spray device of the commercially available nasal spray under the same conditions, the data of D10-D90, for example, the D90 of the nasal cavity soft mist drug delivery device is 23.15 μm, and the D50 is 17.24 μm, while the D90 of the commercially available device is 72.39 μm, and the D50 is 36.28 μm. The nasal cavity soft mist drug delivery device in the present scheme has a narrow distribution of the particle size of the atomized mist droplets, and has a significant advantage in uniformity. And the particle size range of the mist droplets sprayed by the device meets the set range.

[0072] That is, the present scheme provides a better solution for various commercially available nasal sprays. The nasal cavity soft mist drug delivery device of the present scheme can atomize the drug into soft mist with small particle size (5-500 μm), uniform distribution, and slow movement, preferably 20-150 μm particle size, which significantly improves the bioavailability of such drugs, and provides a better compliance option for sensitive patients, elderly patients, and infants and other patients who are not tolerant to bacteriostatic agents.

[0073] The above is only an embodiment of the present application, which is described in detail, but it cannot be understood as a limitation on the scope of the present application. It should be noted that for ordinary skilled persons in the art, without departing from the concept of the present application, a number of modifications and improvements can be made, which all belong to the protection scope of the present application.

Claims

1. A nasal soft mist dosing device, characterized by, The application relates to a medicine administration device, which comprises a medicine administration body and a spray adapter. The spray adapter is connected with the end of the medicine administration body. The medicine administration body is provided with a recess, which divides the internal cavity of the medicine administration body into a first accommodating cavity and a second accommodating cavity in communication. The spray adapter is loaded with a microporous chip, and the microporous chip is opposite to the end position of the medicine administration body. The application further comprises a connecting piece for connecting the spray adapter and the medicine administration body, the connecting piece is provided with an external thread structure, the spray adapter is internally provided with an internal thread structure, and the connecting piece and the spray adapter are screw-connected. The spray adapter is further provided with a guide part, the connecting piece is provided with a through hole, the guide part is arranged in the through hole, one end of the guide part is a pointed structure, and the pointed structure is provided with a liquid outlet hole.

2. A nasal soft mist delivery device according to claim 1, wherein, The inner wall of the through hole is provided with a first limiting part and a second limiting part, and a first groove structure is arranged between the first limiting part and the second limiting part.

3. A nasal soft mist delivery device according to claim 2, wherein, An inner wall of the connecting piece is provided with an inclined angle.

4. A nasal soft mist delivery device according to claim 2, wherein, The end of the medicine administration body is provided with a first convex part, and the first convex part is matched with the first groove.

5. The nasal soft mist dispensing device of claim 1, wherein, The outer surface of the medicine administration body is provided with a second convex part, a second groove is arranged on the connecting piece, and one end of the second convex part is extended and limited into the second groove.

6. The nasal soft mist dispensing device of claim 1, wherein, The end of the medicine administration body is provided with an external thread structure, and the medicine administration body is screw-connected with the spray adapter.

7. The nasal soft mist dispensing device of claim 1, wherein, The lower end of the medicine administration body is provided with a label part, and an information label is attached to the label part.

8. The nasal soft mist dispensing device of claim 1, wherein, The microporous chip is provided with a plurality of spray holes, and the diameter of the spray holes ranges from 1 mu m to 100 mu m.

Images